Verrica Pharmaceuticals Reports 2025 Financial Highlights
- Improved Financial Performance: Verrica Pharmaceuticals reported a narrower net loss of $8.07 million for Q4 2025, translating to a loss of $0.57 per share, significantly down from $16.20 million and $2.41 per share a year earlier, indicating a notable improvement in financial health.
- Significant Revenue Growth: Total revenue for 2025 reached $35.57 million, a substantial increase from $7.56 million the previous year, primarily driven by heightened demand for YCANTH, with product revenue soaring 130% from $6.57 million to $15.28 million.
- Market Expansion Plans: Verrica successfully launched YCANTH in Japan in February 2026 and plans to initiate a second Phase 3 study in mid-2026 to further evaluate VP-102 in the US and Japan, demonstrating the company's proactive approach to entering new markets.
- R&D Progress: The company commenced a global Phase 3 program in December 2025 to evaluate YCANTH for treating common warts, based on positive results from the Phase 2 study, showcasing Verrica's ongoing innovation in dermatological treatments.
Trade with 70% Backtested Accuracy
Analyst Views on VRCA
About VRCA
About the author
Verrica Pharmaceuticals Reports 2025 Financial Highlights
- Improved Financial Performance: Verrica Pharmaceuticals reported a narrower net loss of $8.07 million for Q4 2025, translating to a loss of $0.57 per share, significantly down from $16.20 million and $2.41 per share a year earlier, indicating a notable improvement in financial health.
- Significant Revenue Growth: Total revenue for 2025 reached $35.57 million, a substantial increase from $7.56 million the previous year, primarily driven by heightened demand for YCANTH, with product revenue soaring 130% from $6.57 million to $15.28 million.
- Market Expansion Plans: Verrica successfully launched YCANTH in Japan in February 2026 and plans to initiate a second Phase 3 study in mid-2026 to further evaluate VP-102 in the US and Japan, demonstrating the company's proactive approach to entering new markets.
- R&D Progress: The company commenced a global Phase 3 program in December 2025 to evaluate YCANTH for treating common warts, based on positive results from the Phase 2 study, showcasing Verrica's ongoing innovation in dermatological treatments.
Verrica Pharmaceuticals Reports Strong 2025 Earnings Growth
- Significant Revenue Growth: Verrica Pharmaceuticals reported total revenue of $35.6 million for 2025, marking a 368% year-over-year increase, demonstrating strong market performance driven by the YCANTH product, which is expected to further enhance market share.
- Effective Cost Management: Although R&D expenses rose to $2.5 million, the company successfully reduced selling, general, and administrative expenses by over 40%, indicating effective strategies in cost management that contribute to improved overall profitability.
- Improved Financial Position: The company secured $18 million in milestone payments from its collaboration with Torii Pharmaceuticals and executed a $50 million equity raise, strengthening its financial stability and expected to support future operations and R&D.
- Market Competition Challenges: Despite growth in YCANTH sales, applicator sales saw a sequential decline of approximately 3% in Q4, reflecting issues with gaps in the sales force that could impact future market performance, necessitating close attention to competitor dynamics.
Verrica Pharmaceuticals Reports Strong Revenue Growth Despite EPS Miss
- Earnings Highlights: Verrica Pharmaceuticals reported a FY Non-GAAP EPS of -$1.24, missing expectations by $0.82, indicating ongoing challenges in achieving profitability.
- Significant Revenue Growth: The company achieved revenues of $35.58 million, representing a 370.6% year-over-year increase, surpassing market expectations by $0.58 million, reflecting strong product demand and market share gains.
- Market Reaction: Despite the EPS miss, the robust revenue growth may generate positive sentiment among investors, enhancing confidence in the company's future prospects.
- Strategic Outlook: Verrica's financial performance highlights its potential in the pharmaceutical industry, particularly in terms of new product launches and market expansion, which could lay the groundwork for future investments and growth.
Verrica Initiates Global Phase 3 Trial for YCANTH, Targeting Multibillion-Dollar Market
- Clinical Milestone: Verrica successfully dosed the first patient in December 2025 for its global Phase 3 trial of YCANTH, marking a significant advancement in treating common warts, with the potential to become the first approved therapy in both the U.S. and Japan, addressing the urgent needs of 22 million patients.
- Market Opportunity: With approximately 22 million patients in the U.S. alone, Verrica estimates that the common warts market could represent a multibillion-dollar opportunity, particularly as nearly 50% of these patients are children, indicating strong market potential and future growth prospects.
- Financial Backing: Verrica's recent completion of a $50 million financing and repayment of its debt to OrbiMed provides essential funding for the continued development of YCANTH, enhancing the company's competitive position in the market.
- Cost-Sharing Partnership: Verrica will share the costs of the global Phase 3 trial with Torii, which will fund the first $40 million of trial expenses, approximately 90% of the current budget, alleviating Verrica's financial burden and accelerating the clinical timeline.
Heartbeam Shares Surge Approximately 43%; Check Out 20 Stocks Making Moves in Premarket Trading
Heartbeam Inc's Stock Surge: Heartbeam Inc's shares rose 43.3% in pre-market trading after announcing its regulatory strategy following the FDA's Not Substantially Equivalent decision on its Electrocardiogram Synthesis Software, with plans for an appeal or 510(k) resubmission.
Other Notable Gainers: Several stocks saw significant gains in pre-market trading, including SMX PLC (+73.1%), Zenta Group (+26.7%), and Waton Financial (+21.1%), reflecting a positive trend in the market.
Major Losers: FBS Global Ltd experienced a sharp decline of 24.3%, while Tilray Brands fell 15% after announcing a reverse stock split, indicating volatility among certain stocks.
Market Overview: The pre-market trading session showed mixed results, with notable gains for some companies and significant losses for others, highlighting the fluctuating nature of the stock market.
Biotech and Healthcare Stocks Top After-Hours Gainers: ICU, CGTX, MESO, VRCA, AHCO
Biotech Gains in After-Hours Trading: Several small- and mid-cap biotech and healthcare companies saw significant gains in after-hours trading, driven by corporate updates and financing developments.
SeaStar Medical's Leadership Change: SeaStar Medical's stock rose nearly 10% after the appointment of Michael Messinger as Chief Financial Officer, boosting investor confidence despite no new news.
Cognition Therapeutics' Speculative Buying: Cognition Therapeutics rebounded almost 11% in after-hours trading, likely due to speculative buying interest, following a decline during regular trading hours.
Mesoblast's Revenue Projection: Mesoblast's shares increased after management projected over $30 million in gross revenue for the December quarter, indicating strong demand for its cell therapy product, Ryoncil.
Verrica Pharmaceuticals Reports 2025 Financial Highlights
- Improved Financial Performance: Verrica Pharmaceuticals reported a narrower net loss of $8.07 million for Q4 2025, translating to a loss of $0.57 per share, significantly down from $16.20 million and $2.41 per share a year earlier, indicating a notable improvement in financial health.
- Significant Revenue Growth: Total revenue for 2025 reached $35.57 million, a substantial increase from $7.56 million the previous year, primarily driven by heightened demand for YCANTH, with product revenue soaring 130% from $6.57 million to $15.28 million.
- Market Expansion Plans: Verrica successfully launched YCANTH in Japan in February 2026 and plans to initiate a second Phase 3 study in mid-2026 to further evaluate VP-102 in the US and Japan, demonstrating the company's proactive approach to entering new markets.
- R&D Progress: The company commenced a global Phase 3 program in December 2025 to evaluate YCANTH for treating common warts, based on positive results from the Phase 2 study, showcasing Verrica's ongoing innovation in dermatological treatments.
Verrica Pharmaceuticals Reports Strong 2025 Earnings Growth
- Significant Revenue Growth: Verrica Pharmaceuticals reported total revenue of $35.6 million for 2025, marking a 368% year-over-year increase, demonstrating strong market performance driven by the YCANTH product, which is expected to further enhance market share.
- Effective Cost Management: Although R&D expenses rose to $2.5 million, the company successfully reduced selling, general, and administrative expenses by over 40%, indicating effective strategies in cost management that contribute to improved overall profitability.
- Improved Financial Position: The company secured $18 million in milestone payments from its collaboration with Torii Pharmaceuticals and executed a $50 million equity raise, strengthening its financial stability and expected to support future operations and R&D.
- Market Competition Challenges: Despite growth in YCANTH sales, applicator sales saw a sequential decline of approximately 3% in Q4, reflecting issues with gaps in the sales force that could impact future market performance, necessitating close attention to competitor dynamics.
Verrica Pharmaceuticals Reports Strong Revenue Growth Despite EPS Miss
- Earnings Highlights: Verrica Pharmaceuticals reported a FY Non-GAAP EPS of -$1.24, missing expectations by $0.82, indicating ongoing challenges in achieving profitability.
- Significant Revenue Growth: The company achieved revenues of $35.58 million, representing a 370.6% year-over-year increase, surpassing market expectations by $0.58 million, reflecting strong product demand and market share gains.
- Market Reaction: Despite the EPS miss, the robust revenue growth may generate positive sentiment among investors, enhancing confidence in the company's future prospects.
- Strategic Outlook: Verrica's financial performance highlights its potential in the pharmaceutical industry, particularly in terms of new product launches and market expansion, which could lay the groundwork for future investments and growth.
Verrica Initiates Global Phase 3 Trial for YCANTH, Targeting Multibillion-Dollar Market
- Clinical Milestone: Verrica successfully dosed the first patient in December 2025 for its global Phase 3 trial of YCANTH, marking a significant advancement in treating common warts, with the potential to become the first approved therapy in both the U.S. and Japan, addressing the urgent needs of 22 million patients.
- Market Opportunity: With approximately 22 million patients in the U.S. alone, Verrica estimates that the common warts market could represent a multibillion-dollar opportunity, particularly as nearly 50% of these patients are children, indicating strong market potential and future growth prospects.
- Financial Backing: Verrica's recent completion of a $50 million financing and repayment of its debt to OrbiMed provides essential funding for the continued development of YCANTH, enhancing the company's competitive position in the market.
- Cost-Sharing Partnership: Verrica will share the costs of the global Phase 3 trial with Torii, which will fund the first $40 million of trial expenses, approximately 90% of the current budget, alleviating Verrica's financial burden and accelerating the clinical timeline.
Heartbeam Shares Surge Approximately 43%; Check Out 20 Stocks Making Moves in Premarket Trading
Heartbeam Inc's Stock Surge: Heartbeam Inc's shares rose 43.3% in pre-market trading after announcing its regulatory strategy following the FDA's Not Substantially Equivalent decision on its Electrocardiogram Synthesis Software, with plans for an appeal or 510(k) resubmission.
Other Notable Gainers: Several stocks saw significant gains in pre-market trading, including SMX PLC (+73.1%), Zenta Group (+26.7%), and Waton Financial (+21.1%), reflecting a positive trend in the market.
Major Losers: FBS Global Ltd experienced a sharp decline of 24.3%, while Tilray Brands fell 15% after announcing a reverse stock split, indicating volatility among certain stocks.
Market Overview: The pre-market trading session showed mixed results, with notable gains for some companies and significant losses for others, highlighting the fluctuating nature of the stock market.
Biotech and Healthcare Stocks Top After-Hours Gainers: ICU, CGTX, MESO, VRCA, AHCO
Biotech Gains in After-Hours Trading: Several small- and mid-cap biotech and healthcare companies saw significant gains in after-hours trading, driven by corporate updates and financing developments.
SeaStar Medical's Leadership Change: SeaStar Medical's stock rose nearly 10% after the appointment of Michael Messinger as Chief Financial Officer, boosting investor confidence despite no new news.
Cognition Therapeutics' Speculative Buying: Cognition Therapeutics rebounded almost 11% in after-hours trading, likely due to speculative buying interest, following a decline during regular trading hours.
Mesoblast's Revenue Projection: Mesoblast's shares increased after management projected over $30 million in gross revenue for the December quarter, indicating strong demand for its cell therapy product, Ryoncil.
